跳至主要内容
临床试验/ACTRN12622001166763
ACTRN12622001166763已完成未知

Does anterior cruciate ligament (ACL) injury impair the molecular pathways responsible for building muscle?

Assoc Prof David Opar0 个研究点目标入组 12 人开始时间: 2022年8月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 35 Years(—)
性别
All

入选标准

  • 1.Male or female
  • 2.Aged between 18 to 35 years
  • 3.One leg sustained an ACL injury within the last 5-years, but can safely complete lower limb strength training
  • 4.BMI 18.5-29.9m2

排除标准

  • 1.Any lower limb injury in the past 24-months that influences the quadriceps responses to exercise (e.g. muscle strain)
  • 2.Known cardiovascular disease or diabetes
  • 3.Known bleeding disorder (i.e. hemophilia A [factor VIII deficiency], hemophilia B [factor IX deficiency], von Willebrand disease, or other rare factor deficiencies including I, II, V, VII, X, XI, XII and XIII)
  • 4.Major or chronic illness that impairs mobility or eating/digestion
  • 5.Taking prescription medications (i.e. beta-blockers, anti-arrhythmic drugs, statins, insulin sensitising drugs, or drugs that increase the risk of bleeding [i.e. anticoagulants, antiplatelets, novel oral anticoagulants [NOAs], nonsteroidal anti-inflammatory drugs [NSAIDs], selective norepinephrine reuptake inhibitors [SNRI], or selective serotonin reuptake inhibitors [SSRIs])

研究者

发起方
Assoc Prof David Opar

相似试验